Wikipedia's Clinical Research Glossary: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
** [[English Wikipedia's Glossary of Clinical Research]] [https://en.wikipedia.org/wiki/Glossary_of_clinical_research] | ** [[English Wikipedia's Glossary of Clinical Research]] [https://en.wikipedia.org/wiki/Glossary_of_clinical_research] | ||
** ... | ** ... | ||
* <B>See:</B> [[Clinical Research | * <B>See:</B> [[Clinical Research Terminology]]. | ||
---- | ---- | ||
---- | ---- | ||
Revision as of 20:11, 6 November 2021
A Wikipedia's Clinical Research Glossary is a clinical research glossary that is a Wikipedia-based glossary.
- Example(s):
- See: Clinical Research Terminology.
References
2021
- (Wikipedia, 2021) ⇒ https://en.wikipedia.org/wiki/Glossary_of_clinical_research Retrieved:2021-11-6.
- A glossary of terms used in clinical research.
- Activities of daily living
- Adverse drug reaction
- Adverse effect
- Side effect
- Adverse event
- Adverse reaction
- Animal model
- Animal study
- Approved drugs
- Arm
- Audit report
- Audit trail
- Audit
- Baseline
- Bayesian approaches
- Best practice
- Bias
- Bioavailable
- Bioinformatics
- Biological drug
- Biometrics
- Biometry
- Biostatistics
- Blinded study
- Case report form
- Case report
- Case series
- Case-control study
- Endpoint
- Outcome
- Clinical investigator
- Investigator
- Clinical practice guidelines
- Clinical researcher
- Clinical series
- Clinical study or Clinical trial
- Clinical trial protocol
- Cohort (statistics)
- Cohort study
- Community-based clinical trial (CBCT)
- Comparator
- Compassionate use trial
- Compassionate use
- Complementary and alternative therapy
- Compliance
- Confidentiality regarding trial participants
- Consecutive case series
- Content validity
- Contract Research Organization
- Contract
- Contraindication
- Control group
- Controlled trials
- Controlled clinical trial
- Data and Safety Monitoring Board or Independent Data Monitoring Committee
- Diagnostic trials
- Documentation
- Dose-dependent
- Dose
- Dose-ranging study
- Double-blind study
- Blind
- Dropout
- Drug–drug interaction
- Drug
- Efficacy
- Empirical
- Epidemiology
- Expanded access trial
- Expanded access
- Experimental drug
- Experimental
- Food and Drug Administration (FDA)
- Frequentist methods
- Good clinical practice
- Clinician
- Historic cohort study
- Human subject
- Hypothesis
- In vitro
- In vivo
- Incidence
- Indication
- Informed consent
- Inspection
- Institution
- Institutional Review Board (IRB)
- Inter-rater reliability
- Interaction (Qualitative & Quantitative)
- Advocacy and support groups
- Interim analysis
- ICH E6: Template:Citation
- ICH E9: Template:Citation
- Intra-rater reliability
- Investigational drug
- Investigational New Drug
- Investigator's Brochure
- Levels of evidence
- Masked
- Medication
- Medicine
- Meta-analysis
- Monitoring
- NCI: Template:Citation
- National Institutes of Health
- Natural history study
- New Drug Application (NDA)
- Nonconsecutive case series
- Observation
- Observational study
- Off-label
- Open label study
- Orphan drugs
- Outpatient
- Over-the-counter drug
- Patient advocate
- Peer review
- Pharmacokinetics
- Phase I clinical trials
- Phase II clinical trials
- Phase III clinical trials
- Phase IV clinical trial
- Clinical
- Pilot study
- Placebo effect
- Placebo controlled study
- Placebo
- Population study
- Preclinical
- Prevention
- Prospective cohort study
- Quality Assurance
- Quality of life trials (or supportive care trials)
- Randomization
- Randomized clinical trial
- Recruiting
- Regimen
- Retrospective cohort study
- Retrospective
- Risk-benefit ratio
- Control
- Selection bias
- Single blind study
- Sponsor
- Standard Operating Procedures
- Standard treatment
- Standards of care
- Statistical significance
- Significant
- Study endpoint
- t-test
- 21CFR312.3: Template:Citation
- 21CFR50.3: Template:Citation
- Toxicity
- Treatment IND
- NLM: Template:Citation
- Applicable regulatory requirement
- Approval (in relation to institutional review boards (IRBs))
- Audit certificate
- Blind review
- Clinical investigation
- Clinical Trial/Study Report
- Control animal
- Coordinating Committee
- Coordinating Investigator
- Direct Access
- Dose-limiting
- Dose-rate
- Double-dummy
- Eligibility criteria
- Enrolling
- Equivalence trial
- Essential Documents
- Evaluable disease
- Evaluable patients
- Follow-up
- Full analysis set
- Generalisability, Generalisation
- Global assessment variable
- Healthy control
- Historical control subject
- Impartial Witness
- Inclusion/exclusion criteria
- Independent Ethics Committee
- Informed consent document
- Intent to treat
- Interim Clinical Trial/Study Report
- Intervention group
- Intervention name
- Intervention
- Investigational
- Legally Acceptable Representative
- Maximum tolerated dose
- Monitoring Report
- Multicenter study
- Multidisciplinary opinion
- Multiplicity
- Non-inferiority trial
- Nonblinded
- Nonclinical Study
- Nonrandomized clinical trial
- Objective improvement
- Objective response
- Per protocol set (Valid Cases, Efficacy Sample, Evaluable Subjects Sample)
- Phase I/II trial
- Phase II/III trial
- Placebo therapy
- Predictive factor
- Prevention trials
- Preventive
- Primary endpoint
- Prospective
- Protocol Amendment
- Quality Control
- Recruitment status
- Regulatory Authorities
- Retrospective study
- Safety & tolerability
- Screening trials
- Serious Adverse Event
- Sham therapy
- Source Data
- Source Documents
- Sponsor-Investigator
- Statistical analysis plan
- Study type
- Subinvestigator
- Subject Identification Code
- Subject/Trial Subject
- Superiority trial
- Surrogate variable
- Test article
- Treatment effect
- Treatment emergent
- Treatment trials
- Trial Site
- Trial statistician
- Uncontrolled study
- Unexpected Adverse Drug Reaction
- Vulnerable Subjects
- Well-being of the trial subjects